vs
BGC Group, Inc.（BGC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BGC Group, Inc.的1.2倍（$772.1M vs $638.6M），Revvity净利率更高（12.7% vs 2.3%，领先10.5%），BGC Group, Inc.同比增速更快（34.4% vs 5.9%），BGC Group, Inc.自由现金流更多（$175.1M vs $161.8M），过去两年BGC Group, Inc.的营收复合增速更高（18.7% vs 9.0%）
BGC集团是一家总部位于纽约和伦敦的美国全球性金融服务企业，最初隶属于康托·菲茨杰拉德集团，2004年正式独立运营，业务范围覆盖全球金融市场相关服务领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BGC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$638.6M
营收增速更快
BGC
高出28.5%
5.9%
净利率更高
RVTY
高出10.5%
2.3%
自由现金流更多
BGC
多$13.3M
$161.8M
两年增速更快
BGC
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $638.6M | $772.1M |
| 净利润 | $14.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | 14.5% |
| 净利率 | 2.3% | 12.7% |
| 营收同比 | 34.4% | 5.9% |
| 净利润同比 | -43.0% | 3.9% |
| 每股收益（稀释后） | $0.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGCRVTY
| Q4 25 | $638.6M | $772.1M | ||
| Q3 25 | $620.8M | $698.9M | ||
| Q2 25 | $648.0M | $720.3M | ||
| Q1 25 | $534.6M | $664.8M | ||
| Q4 24 | $475.2M | $729.4M | ||
| Q3 24 | $448.9M | $684.0M | ||
| Q2 24 | $435.0M | $691.7M | ||
| Q1 24 | $453.6M | $649.9M |
净利润BGCRVTY
| Q4 25 | $14.4M | $98.4M | ||
| Q3 25 | $27.9M | $46.7M | ||
| Q2 25 | $57.5M | $53.9M | ||
| Q1 25 | $55.2M | $42.2M | ||
| Q4 24 | $25.2M | $94.6M | ||
| Q3 24 | $14.7M | $94.4M | ||
| Q2 24 | $37.8M | $55.4M | ||
| Q1 24 | $49.2M | $26.0M |
毛利率BGCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率BGCRVTY
| Q4 25 | 3.9% | 14.5% | ||
| Q3 25 | 5.4% | 11.7% | ||
| Q2 25 | 11.6% | 12.6% | ||
| Q1 25 | 15.0% | 10.9% | ||
| Q4 24 | 5.7% | 16.3% | ||
| Q3 24 | 4.4% | 14.3% | ||
| Q2 24 | 12.7% | 12.4% | ||
| Q1 24 | 15.7% | 6.8% |
净利率BGCRVTY
| Q4 25 | 2.3% | 12.7% | ||
| Q3 25 | 4.5% | 6.7% | ||
| Q2 25 | 8.9% | 7.5% | ||
| Q1 25 | 10.3% | 6.4% | ||
| Q4 24 | 5.3% | 13.0% | ||
| Q3 24 | 3.3% | 13.8% | ||
| Q2 24 | 8.7% | 8.0% | ||
| Q1 24 | 10.8% | 4.0% |
每股收益（稀释后）BGCRVTY
| Q4 25 | $0.03 | $0.86 | ||
| Q3 25 | $0.06 | $0.40 | ||
| Q2 25 | $0.11 | $0.46 | ||
| Q1 25 | $0.11 | $0.35 | ||
| Q4 24 | $0.04 | $0.77 | ||
| Q3 24 | $0.03 | $0.77 | ||
| Q2 24 | $0.08 | $0.45 | ||
| Q1 24 | $0.10 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $851.5M | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $972.5M | $7.3B |
| 总资产 | $4.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.58× | — |
8季度趋势，按日历期对齐
现金及短期投资BGCRVTY
| Q4 25 | $851.5M | $919.9M | ||
| Q3 25 | $774.9M | $931.4M | ||
| Q2 25 | $827.8M | $991.8M | ||
| Q1 25 | $966.4M | $1.1B | ||
| Q4 24 | $711.6M | $1.2B | ||
| Q3 24 | $563.5M | $1.2B | ||
| Q2 24 | $571.7M | $2.0B | ||
| Q1 24 | $566.8M | $1.7B |
总债务BGCRVTY
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $945.0M | — |
股东权益BGCRVTY
| Q4 25 | $972.5M | $7.3B | ||
| Q3 25 | $965.3M | $7.4B | ||
| Q2 25 | $930.5M | $7.6B | ||
| Q1 25 | $963.8M | $7.6B | ||
| Q4 24 | $898.5M | $7.7B | ||
| Q3 24 | $860.1M | $7.9B | ||
| Q2 24 | $858.1M | $7.9B | ||
| Q1 24 | $912.1M | $7.8B |
总资产BGCRVTY
| Q4 25 | $4.4B | $12.2B | ||
| Q3 25 | $5.8B | $12.1B | ||
| Q2 25 | $4.9B | $12.4B | ||
| Q1 25 | $4.9B | $12.4B | ||
| Q4 24 | $3.6B | $12.4B | ||
| Q3 24 | $4.4B | $12.8B | ||
| Q2 24 | $4.3B | $13.4B | ||
| Q1 24 | $4.4B | $13.4B |
负债/权益比BGCRVTY
| Q4 25 | 1.58× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.97× | — | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 1.68× | — | ||
| Q1 24 | 1.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $180.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $175.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 27.4% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 12.55× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $372.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BGCRVTY
| Q4 25 | $180.4M | $182.0M | ||
| Q3 25 | $141.9M | $138.5M | ||
| Q2 25 | $71.2M | $134.3M | ||
| Q1 25 | $839.0K | $128.2M | ||
| Q4 24 | $251.9M | $174.2M | ||
| Q3 24 | $88.3M | $147.9M | ||
| Q2 24 | $-53.0M | $158.6M | ||
| Q1 24 | $28.1M | $147.6M |
自由现金流BGCRVTY
| Q4 25 | $175.1M | $161.8M | ||
| Q3 25 | $137.2M | $120.0M | ||
| Q2 25 | $65.0M | $115.5M | ||
| Q1 25 | $-4.4M | $112.2M | ||
| Q4 24 | $245.6M | $149.8M | ||
| Q3 24 | $78.8M | $125.6M | ||
| Q2 24 | $-63.5M | $136.6M | ||
| Q1 24 | $24.9M | $129.7M |
自由现金流率BGCRVTY
| Q4 25 | 27.4% | 21.0% | ||
| Q3 25 | 22.1% | 17.2% | ||
| Q2 25 | 10.0% | 16.0% | ||
| Q1 25 | -0.8% | 16.9% | ||
| Q4 24 | 51.7% | 20.5% | ||
| Q3 24 | 17.5% | 18.4% | ||
| Q2 24 | -14.6% | 19.7% | ||
| Q1 24 | 5.5% | 20.0% |
资本支出强度BGCRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.0% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 0.7% | 2.7% |
现金转化率BGCRVTY
| Q4 25 | 12.55× | 1.85× | ||
| Q3 25 | 5.09× | 2.97× | ||
| Q2 25 | 1.24× | 2.49× | ||
| Q1 25 | 0.02× | 3.03× | ||
| Q4 24 | 9.99× | 1.84× | ||
| Q3 24 | 5.99× | 1.57× | ||
| Q2 24 | -1.40× | 2.87× | ||
| Q1 24 | 0.57× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGC
| Commissions | $590.2M | 92% |
| Data Software And Post Trade | $36.7M | 6% |
| Fees From Related Parties | $4.6M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
